Knowledge in Motion SCI Education Series: New Advances in Research for Recovery after SCI

Starts:
6:30 pm on Thursday, June 13, 2013
Ends:
8:00 pm on Thursday, June 13, 2013
Knowledge in Motion SCI Education Series New Advances in Research for Recovery after SCI Thursday, June 13, 2013 6:30-8:00 PM Eastern Time presented by Jeffrey D. Macklis, MD Harvard Stem Cell Institute Harvard University Harvard Medical School Lisa McKerracher, Ph.D. BioAxone BioSciences, Inc. Angus McQuilken Massachusetts Life Sciences Center Frank Reynolds Invivo Therapeutics To attend Free Online Webcast and Live Chat Register here or contact: Judi.Zazula@bmc.org 617-638-7314 866-607-1804 (toll-free) To attend Dinner and Evening Lecture Cost: $10 before 6-3-13; $20 at the door Register here or contact: Helen Stott at hstott@partners.org 617-952-6173 Spaulding’s New Location! 300 First Ave., 1st fl. Cafeteria Charlestown, MA 02129 About this month’s topic: A panel of speakers will join us to discuss current research into SCI treatments. Jeffrey Macklis, MD, Harvard Stem Cell institute, Professor of Stem Cell and Regenerative Biology at Harvard University, and Professor of Neurology and Neurosurgery at Harvard Medical School, will discuss the basic neurons and circuitry that connect the brain to the spinal cord. He will talk about the kinds of nerve injuries that are central to loss of muscle strength in SCI. Repair, regeneration, and/or replacement of these neurons by developmental and stem cell biology might provide useful, real-world therapies for real people who have lost motor function and bowel/bladder control due to SCI. Dr. Macklis will highlight a brand new set of approaches that his lab is using to pursue this goal. Lisa McKerracher, PhD, Founder, BioAxone Biosciences, will present on some studies showing that neurons in the spinal cord have the capacity for regeneration and repair. She will also describe BioAxone’s efforts to develop a drug called Cethrin™. Cethrin is new therapeutic protein in Phase II clinical development for the treatment of acute spinal cord injury. It has shown exceptional promise in promoting motor recovery in quadriplegic patients. BioAxone Biosciences Inc. is a privately owned American Corporation with a focus on bringing drugs to market for unmet medical needs. Angus McQuilken, Vice President for Communications & Marketing at the Massachusetts Life Sciences Center, will present on the investments being made by the Massachusetts Life Sciences Center that relate to SCI research and patient treatment. He will talk about the state’s 10-year, $1-billion Life Sciences Initiative and its relevance to the SCI community. The Massachusetts Life Sciences Center is a quasi-public agency of the Commonwealth of Massachusetts. The Center’s mission is to create jobs in the life sciences and support vital scientific research that will improve the human condition. Frank Reynolds, Co-Founder, InVivo Therapeutics, will talk about the relationship of biomaterials to SCI treatments. Whether minimizing secondary injury in the weeks after the primary injury, or supporting neuroplasticity during the patient’s recovery, biomaterial based interventions led by neuroscientists and chemical engineers from MIT are providing new ideas on how SCI patients will be treated in the near future. InVivo’s technologies integrate multiple strategies involving biomaterials, FDA approved drugs, growth factors, and human neural stem cells. Mr. Reynolds will discuss these technologies as well as their impact on SCI patients. Support Group Meetings (Boston) There will be a GBC NSCIA peer support group meeting beginning at 5:00 PM. A family support group will begin at 5:15 PM. For more info, call 617-952-5643.